Biogen Multiple Sclerosis Pregnancy Exposure Registry

CompletedOBSERVATIONAL
Enrollment

408

Participants

Timeline

Start Date

October 30, 2013

Primary Completion Date

February 10, 2022

Study Completion Date

February 10, 2022

Conditions
Multiple SclerosisExposure During Pregnancy
Interventions
DRUG

Dimethyl fumarate

Administered as specified in treatment arm.

DRUG

Peginterferon beta-1a

Administered as specified in treatment arm.

Trial Locations (15)

3128

Research Site, Box Hill

16132

Research Site, Genova

20132

Research Site, Milan

28034

Research Site, Madrid

29010

Research Site, Málaga

44791

Research Site, Bochum

50134

Research Site, Florence

69677

Research Site, Bron

90146

Research Site, Palermo

02139-1955

Research Site, Cambridge

Research Site, Cambridge

D04 T6F4

Research Site, Dublin

00152

Research Site, Roma

15-276

Research Site, Bialystok

M6 8HD

Research Site, Salford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY